Matches in SemOpenAlex for { <https://semopenalex.org/work/W2754881036> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- W2754881036 abstract "Background Methotrexate (Mtx) should be the drug of the first choice in rheumatoid arthritis (RA) if there are no contraindications to use it. The efficacy of Mtx is measured by remission or low disease activity and depends on the dose taken. Higher doses (25–30 mg/week) are more effective, but intolerance is the main cause of discontinuation of oral treatment. Subcutaneous Mtx is efficient alternative in those cases. Objectives The aim of this study was to evaluate subcutaneous Mtx use frequency in Polish patients and change oral form for subcutaneous as well. Methods The disease activity was assessed by Disease Activity Score 28 (DAS 28) during the first visit (V1) and after 3 months therapy (V2) and compliance with therapy as well. Results There were 194 RA patients diagnosed by the ACR and 1997 and/or ACR/EULAR 2010 criteria. 144 patients were treated by oral Mtx (group A) and 50 patients (group B) by subcutaneous Mtx at the time of study enrolment (V1).37 patients of group A (26%) required changes in therapy during V2, 24 (17%) were switched to subcutaneous Mtx (group A1). 6 patients of group B (12%) required change of treatment during V2, including 2 patients (4%) with subcutaneous Mtx, who were switched to oral Mtx.The main cause of changing therapy from oral to subcutaneous was gastrointestinal intolerance of high dose of Mtx. 69 patients (12%) of group A required additional steroid therapy compared to 18 (36%) of group B. Average DAS 28 decreased by 0.58 in group A1 in oral treatment and during the subcutaneous treatment time decreased by next 0.23. In group A1 during oral treatment 14 (58%) patients used 25 mg/week and 20 patients (83%) used 25 mg/week during subcutaneous treatment time. Conclusions Patients treatment by oral Mtx often require modification of therapy in comparison to patients treated by subcutaneous Mtx, including more frequent use of steroids The main cause of oral intolerance are ailments of the digestive system. Change of oral to subcutaneous therapy allows administration of higher doses of Mtx and results in decrease of DAS28 in comparison to the patients continuing their oral treatment. Disclosure of Interest None declared" @default.
- W2754881036 created "2017-09-25" @default.
- W2754881036 creator A5029199392 @default.
- W2754881036 creator A5034523780 @default.
- W2754881036 creator A5039577905 @default.
- W2754881036 creator A5082246763 @default.
- W2754881036 date "2017-06-01" @default.
- W2754881036 modified "2023-09-27" @default.
- W2754881036 title "AB1211-HPR The use of subcutaneous methotrexate in polish patients with rheumatoid arthritis" @default.
- W2754881036 doi "https://doi.org/10.1136/annrheumdis-2017-eular.6963" @default.
- W2754881036 hasPublicationYear "2017" @default.
- W2754881036 type Work @default.
- W2754881036 sameAs 2754881036 @default.
- W2754881036 citedByCount "0" @default.
- W2754881036 crossrefType "proceedings-article" @default.
- W2754881036 hasAuthorship W2754881036A5029199392 @default.
- W2754881036 hasAuthorship W2754881036A5034523780 @default.
- W2754881036 hasAuthorship W2754881036A5039577905 @default.
- W2754881036 hasAuthorship W2754881036A5082246763 @default.
- W2754881036 hasBestOaLocation W27548810361 @default.
- W2754881036 hasConcept C126322002 @default.
- W2754881036 hasConcept C141071460 @default.
- W2754881036 hasConcept C2776390293 @default.
- W2754881036 hasConcept C2777575956 @default.
- W2754881036 hasConcept C2777785397 @default.
- W2754881036 hasConcept C2778715236 @default.
- W2754881036 hasConcept C2781059491 @default.
- W2754881036 hasConcept C71924100 @default.
- W2754881036 hasConcept C90924648 @default.
- W2754881036 hasConceptScore W2754881036C126322002 @default.
- W2754881036 hasConceptScore W2754881036C141071460 @default.
- W2754881036 hasConceptScore W2754881036C2776390293 @default.
- W2754881036 hasConceptScore W2754881036C2777575956 @default.
- W2754881036 hasConceptScore W2754881036C2777785397 @default.
- W2754881036 hasConceptScore W2754881036C2778715236 @default.
- W2754881036 hasConceptScore W2754881036C2781059491 @default.
- W2754881036 hasConceptScore W2754881036C71924100 @default.
- W2754881036 hasConceptScore W2754881036C90924648 @default.
- W2754881036 hasLocation W27548810361 @default.
- W2754881036 hasOpenAccess W2754881036 @default.
- W2754881036 hasPrimaryLocation W27548810361 @default.
- W2754881036 hasRelatedWork W119744193 @default.
- W2754881036 hasRelatedWork W2009926255 @default.
- W2754881036 hasRelatedWork W2011631721 @default.
- W2754881036 hasRelatedWork W2012748985 @default.
- W2754881036 hasRelatedWork W2042215069 @default.
- W2754881036 hasRelatedWork W2054531569 @default.
- W2754881036 hasRelatedWork W2077435758 @default.
- W2754881036 hasRelatedWork W2134773895 @default.
- W2754881036 hasRelatedWork W2148050165 @default.
- W2754881036 hasRelatedWork W2152705401 @default.
- W2754881036 hasRelatedWork W2260957858 @default.
- W2754881036 hasRelatedWork W2357025913 @default.
- W2754881036 hasRelatedWork W2361180466 @default.
- W2754881036 hasRelatedWork W2367380270 @default.
- W2754881036 hasRelatedWork W2418119539 @default.
- W2754881036 hasRelatedWork W2756212857 @default.
- W2754881036 hasRelatedWork W2909708333 @default.
- W2754881036 hasRelatedWork W2964753644 @default.
- W2754881036 hasRelatedWork W3049330814 @default.
- W2754881036 hasRelatedWork W3120986071 @default.
- W2754881036 isParatext "false" @default.
- W2754881036 isRetracted "false" @default.
- W2754881036 magId "2754881036" @default.
- W2754881036 workType "article" @default.